Artificial Intelligence Leadership and Strategy (AILS)

Q_01 domain/d1 · medium single discuss →

A pharmaceutical company wants to increase agility across its business. Its transformation lead argues that manufacturing processes for its regulated medicines should be made just as highly agile as its marketing function. According to the source material, why is this recommendation flawed?

A Agility can only ever be applied to marketing and distribution, never to any production activity
B Different levels of agility capability are expected across a business, and high agility in regulated manufacturing would be highly undesirable
C Manufacturing cannot benefit from agility because Scrum is limited to teams of 10 or fewer members
D Agility should be applied uniformly everywhere, so singling out manufacturing is the real problem

Q_02 domain/d1 · medium single discuss →

An executive sponsor asks how the organisation will justify continued investment in its business agility initiative to the board. Based on the source material, what should be established before the initiative begins to make trends in performance meaningful?

A A single composite agility maturity score to be tracked quarterly
B A baseline of current business performance across a wide range of measures, plus baselined indicators of the people aspects of agility
C A fixed target date by which the entire organisation must be fully agile
D A contractual commitment from every team to adopt Scrum simultaneously

Q_03 domain/d1 · medium single

Locked question — unlock this exam to view it.

Explanation

Explanation